The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 12, 2013
Filed:
Sep. 07, 2011
Lewis T. Williams, Mill Valley, CA (US);
Elizabeth Bosch, Cupertino, CA (US);
Stephen Doberstein, San Francisco, CA (US);
Kevin Hestir, Kensington, CA (US);
Diane Hollenbaugh, Mountain View, CA (US);
Ernestine Lee, Kensington, CA (US);
Minmin Qin, Pleasanton, CA (US);
Ali Sadra, San Mateo, CA (US);
Justin Wong, Oakland, CA (US);
GE Wu, La Canada, CA (US);
Hongbing Zhang, Albany, CA (US);
Lewis T. Williams, Mill Valley, CA (US);
Elizabeth Bosch, Cupertino, CA (US);
Stephen Doberstein, San Francisco, CA (US);
Kevin Hestir, Kensington, CA (US);
Diane Hollenbaugh, Mountain View, CA (US);
Ernestine Lee, Kensington, CA (US);
Minmin Qin, Pleasanton, CA (US);
Ali Sadra, San Mateo, CA (US);
Justin Wong, Oakland, CA (US);
Ge Wu, La Canada, CA (US);
Hongbing Zhang, Albany, CA (US);
Five Prime Therapeutics, Inc., South San Francisco, CA (US);
Abstract
The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.